Novo Nordisk stock price forecast: expanding obesity portfolio lifts NVO as price hits $58.84

Traders Union
All News
Financial News
Novo Nordisk jumps 2.62% to $58.84

Highlights

Novo Nordisk launched an affordable oral version of its Wegovy weight-loss treatment in the US, expanding its portfolio beyond injectables.
The introduction of the Wegovy pill targets greater market share and improved access for patients needing weight-loss medications.
This product development is the main driver of positive sentiment for Novo Nordisk today.

Market optimism builds as new oral Wegovy targets wider patient base

Novo Nordisk has expanded its weight-loss portfolio by launching an affordable oral version of its Wegovy treatment in the US, marking a strategic push to grow market share and improve access to its weight-loss medications. The pill offering represents a significant departure from the company's historical reliance on injectable therapies and signals intent to reach a broader segment of patients. This notable product development is the main driver of sentiment today.

Upside resistance and overbought signals as momentum diverges

The asset is trading above the Ichimoku Kijun ($53.36), building dynamic support in the $53–54 zone, while resistance is likely at $59–60. The MACD issues a "Buy" signal and the ADX points to a neutral daily trend, though weekly momentum weakens. RSI has reached an overbought reading (75.49), while both Stochastic RSI and CCI confirm stretched conditions; Bull/Bear Power shows strong buyer dominance intraday. The Awesome Oscillator aligns with the bullish trend, and current price action suggests moderate volatility as the price holds mid-range for the session, creating a divergence between overbought signals and persistent bullish tone.

Near-term consolidation likely as overbought risks outweigh further gains

Over the next five trading days, typical volatility is expected in a $58.80 to $60.30 band. Technicals suggest a very low probability (less than 20%) of further price gains and a higher likelihood of a decrease, favoring near-term consolidation near current levels as bulls face overbought conditions. A sustained break above $60 could open the way to $61, while a move below $58.80 would put support around $57.50 into play.

Anton Kharitonov, expert at Traders Union, sees short-term bullish momentum for Novo Nordisk A/S supported by technical strength above key moving averages. He notes the recent product launch adds to positive sentiment, but also observes widespread overbought readings and resistance near $59–60. Kharitonov says buyers may struggle to extend gains, and consolidation is likely as conditions normalize. "Until price convincingly breaks above $60, I remain cautious as the risk of a pullback outweighs the chance of a further surge."

Last time, analysts noted that Novo Nordisk A/S was exhibiting strong short- and medium-term bullish momentum, trading well above its key moving averages and supported by positive MACD alongside elevated intraday buying strength. However, with multiple oscillators including RSI, Stoch RSI, and CCI indicating overbought conditions near long-term resistance, the risk of short-term mean reversion was seen as elevated despite ongoing upward momentum.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.